First Commonwealth Financial Corp
Change company Symbol lookup
Select an option...
FCF First Commonwealth Financial Corp
PTOTF Patriot One Technologies Inc
GIM Templeton Global Income Fund
NSTC Northern Star Investment Corp III
WMLLF Wealth Minerals Ltd
NVVE Nuvve Holding Corp
ICCC ImmuCell Corp
MET MetLife Inc
FAST Fastenal Co
PFTA Portage Fintech Acquisition Corp
Go

Financials : Banks | Small Cap Value
Company profile

First Commonwealth Financial Corporation is a financial holding company for First Commonwealth Bank (the Bank). First Commonwealth Bank is a Pennsylvania bank and trust company. The Bank provides a diversified array of consumer and commercial banking services. It also provides trust and wealth management services and offers insurance products through the Bank and its other operating subsidiaries. The Bank operates approximately 118 community banking offices throughout western and central Pennsylvania, and northeastern, central and southwestern Ohio, as well as corporate banking centers in Pittsburgh, Pennsylvania, and Columbus, Canton and Cleveland, Ohio, and mortgage banking offices in Wexford, Pennsylvania, and Hudson, Westlake and Lewis Center, Ohio. The Bank also operates a network of approximately 136 automated teller machines (ATMs), at various branch offices and offsite locations.

Price
Delayed
$14.47
Day's Change
-0.005 (-0.03%)
Bid
--
Ask
--
B/A Size
--
Day's High
14.53
Day's Low
14.39
Volume
(Light)

Today's volume of 41,201 shares is on pace to be much lighter than FCF's 10-day average volume of 338,523 shares.

41,201

Gainey McKenna & Egleston Filed The First Class Action Lawsuit Against Kiromic BioPharma, Inc. (KRBP); The Class Period Has Been Enlarged from June 25, 2021 to February 2, 2022; And The Motion Deadline For Lead Plaintiff Is Today

12:29 pm ET October 4, 2022 (Globe Newswire) Print
Gainey McKenna & Egleston Filed The First Class Action Lawsuit Against Kiromic BioPharma, Inc. (KRBP); The Class Period Has Been Enlarged from June 25, 2021 to February 2, 2022; And The Motion Deadline For Lead Plaintiff Is TodayGlobeNewswireOctober 04, 2022

NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston filed the first class action lawsuit against Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP) and against certain officers and directors of the Company regarding the allegations below. The proposed class period has been enlarged to now be on behalf of a class consisting of all persons and entities that purchased or otherwise acquired Kiromic securities between June 25, 2021 and February 2, 2022, both dates inclusive (the "Class Period").

The Company's public offering closed on July 2, 2021 (the "Offering") and was conducted pursuant to a registration statement filed with the SEC on June 25, 2021 ("Registration Statement") and a final prospectus dated June 29, 2021 (the "Prospectus," with the Registration Statement, the "Offering Documents").

The Complaint alleges that the Offering Documents failed to disclose that the FDA had, prior to the filing of the Registration Statement and Prospectus, imposed a clinical hold, and in fact, contained statements indicating that it had not. Given that the Offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.

The Company, however, had received communications from the FDA on June 16 and 17, 2021, informing it that the FDA was placing the IND applications for its two candidate products on clinical hold. The Offering Documents failed to disclose this information, instead representing that clinical testing was expected to proceed in the third quarter of 2021. Clinical testing did not proceed in the third quarter of 2021, nor was it likely given the FDA's imposition of a clinical hold.

Investors who purchased or otherwise acquired shares of Kiromic should contact the Firm prior to the October 4, 2022 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at tjmckenna@gme-law.com or gegleston@gme-law.com.

Please visit our website at http://www.gme-law.com for more information about the firm.



comtex tracking

COMTEX_415910170/2010/2022-10-04T12:29:23

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.